Keywords: mixed, late-stage, data, b-ms/medarex, ipilimumab, usa-based, biopharmaceutical
Mixed late-stage data on B-MS/Medarex' ipilimumab
Article | 17 December 2007
USA-based biopharmaceutical company Medarex and drug major Bristol-Myers Squibb have reported mixed top-line data on their co-developed anticancer drug candidate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
